Autogene cevumeran

Biologic

Roche

Indications

Total Trials

Active Trials

Competitors

Timeline

Expected Milestones

Q4 2027

Phase 2Active, not recruiting

Transitional Cell Carcinoma

NCT06534983

Q1 2031

Phase 2Active, not recruiting

Adenocarcinoma, Pancreatic Ductal

NCT05968326

Clinical

Trials by Indication[1]

Metastatic Tumors1 trial

A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT03289962·272 enrolled

Melanoma1 trial

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

Completed· Roche logo

Roche·Phase 2·NCT03815058·131 enrolled

Transitional Cell Carcinoma1 trial

A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma

Active, not recruiting· Roche logo

Roche·Phase 2·NCT06534983·62 enrolled

Adenocarcinoma, Pancreatic Ductal1 trial

A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05968326·260 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Autogene cevumeran. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Autogene cevumeran compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: Roche